Zobrazeno 1 - 10
of 946
pro vyhledávání: '"Sumanta K, Pal"'
Autor:
Hedyeh Ebrahimi, Dena Battle, Nicholas J. Salgia, Zeynep B. Zengin, Nazli Dizman, Luis Meza, Cristiane D. Bergerot, Regina Barragan-Carrillo, JoAnn Hsu, Daniela Castro, Benjamin Mercier, Neal Chawla, Xiaochen Li, Abhishek Tripathi, Sandy T. Liu, Alex Chehrazi-Raffle, Ulka Vaishampayan, Michael D. Staehler, Sumanta K. Pal
Publikováno v:
Nutrients, Vol 16, Iss 11, p 1630 (2024)
Many patients diagnosed with cancer adopt dietary changes and supplement use, and a growing body of evidence suggests that such modifications can affect outcomes to cancer therapy. We sought to assess the prevalence of these practices and the surroun
Externí odkaz:
https://doaj.org/article/06e6f35dc732492abffa3b9a9898817f
Autor:
Marice B. Alcantara, Wilson S. Tang, Dongfang Wang, Damian Kaniowski, Elaine Kang, Nazli Dizman, Alexander Chehrazi-Raffle, Luis Meza, Zeynep Zengin, Jeremy Hall, JoAnn Hsu, Colt Egelston, Dayson Moreira, Alan Horsager, Sumanta K. Pal, Marcin Kortylewski
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
IntroductionImmune checkpoint blockade (ICB) improved clinical outcomes in renal and bladder cancer patients, but the response rates remain limited especially in metastatic disease. While STAT3 transcription factor is well-known master regulator of t
Externí odkaz:
https://doaj.org/article/dd84707eb9c14a5ba4ee11901b173fa0
Autor:
Huan Wang, Nina Bhardwaj, Naoko Imai, Seunghee Kim-Schulze, Takuro Saito, Jingjing Qi, Sacha Gnjatic, Sumanta K Pal, Matthew D Galsky, Manishkumar Patel, Hui Xie, Robert Sebra, Andrew Uzilov, Jonathan Anker, Rebecca Halperin, Shingo Eikawa, Noah M Hahn
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Cisplatin-based chemotherapy has been associated with durable disease control in a small subset of patients with metastatic urothelial cancer. However, the mechanistic basis for this phenomenon has remained elusive. Antitumor immunity may underlie th
Externí odkaz:
https://doaj.org/article/55cbcba3ae0649aeb88c87f1c18bdaa7
Autor:
Ameish Govindarajan, Nicholas J. Salgia, Haiqing Li, Daniela V. Castro, Tamara Mirzapoiazova, Brian Armstrong, Dan Zhao, Benjamin D. Mercier, Nazli Dizman, Neal Chawla, Zeynep Zengin, Luis Meza, Nishita Tripathi, Nicolas Sayegh, Alex Chehrazi-Raffle, Abhishek Tripathi, Sumanta K. Pal
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
ObjectiveTo characterize and further compare the immune cell populations of the tumor microenvironment (TME) in both clear cell and papillary renal cell carcinoma (RCC) using heavy metal-labeled antibodies in a multiplexed imaging approach (imaging m
Externí odkaz:
https://doaj.org/article/151b8f04129a483a9b5f27668a5f2782
Autor:
Diego Abreu, Gustavo Carvalhal, Guillermo Gueglio, Ignacio Tobia, Patricio Garcia, Alvaro Zuñiga, Luis Meza, Rubén Bengió, Carlos Scorticati, Ricardo Castillejos, Francisco Rodriguez, Ana María Autran, Carmen Gonzales, Jose Gadu, Alejandro Nolazco, Carlos Ameri, Hamilton Zampolli, Raúl Langenhin, Diego Muguruza, Marcos Tobías Machado, Pablo Mingote, Juan Yandian, Jorge Clavijo, Lucas Nogueira, Omar Clark, Fernando Secin, Agustín Rovegno, Ana Vilas, Enrique Barrios, Ricardo Decia, Gustavo Guimarães, Sidney Glina, Sumanta K. Pal, Oscar Rodriguez, Joan Palou, Philippe Spiess, Primo N. Lara, W. Marston Linehan, Antonio Luigi Pastore, Stenio C. Zequi
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 671-685 (2021)
PURPOSETo assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries.PATIENTS AND METHODSOf 4,060 patients with renal
Externí odkaz:
https://doaj.org/article/c8a760862ef940b5b22a76bac36c636f
Autor:
Chung-Wei Lee, Thomas Powles, Sabina Signoretti, David F McDermott, Sumanta K Pal, Toni K Choueiri, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Scott S Tykodi, Nizar M Tannir, Saurabh Gupta, Ruiyun Jiang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Background Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and limited therapeutic options. First-line nivolumab plus ipilimumab (NIVO+IPI) provided efficacy benefits over sunitinib (SUN) in patients
Externí odkaz:
https://doaj.org/article/635447aa98714bc2a7c7b60e0478a8aa
Publikováno v:
European Urology Open Science, Vol 48, Iss , Pp 70-71 (2023)
Externí odkaz:
https://doaj.org/article/039268447f2c40d28c9dce51c3de75d1
Autor:
Nicholas J. Salgia, Alexander Chehrazi‐Raffle, JoAnn Hsu, Zeynep Zengin, Sabrina Salgia, Neal S. Chawla, Luis Meza, Jasnoor Malhotra, Nazli Dizman, Ramya Muddasani, Nora Ruel, Mary Cianfrocca, Jun Gong, Sidharth Anand, Victor Chiu, James Yeh, Sumanta K. Pal
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5671-5680 (2021)
Abstract Background Tertiary cancer centers offer clinical expertise and multi‐modal approaches to treatment alongside the integration of research protocols. Nevertheless, most patients receive their cancer care at community practices. A better und
Externí odkaz:
https://doaj.org/article/3247895c6c634ff285bccc140d3b7306
Autor:
Umang Swami, Raquel Mae Zimmerman, Roberto H. Nussenzveig, Edgar Javier Hernandez, Yeonjung Jo, Nicolas Sayegh, Sergiusz Wesolowski, Lesli A. Kiedrowski, Pedro C. Barata, Gordon Howard Lemmon, Mehmet A. Bilen, Elisabeth I. Heath, Lakshminarayan Nandagopal, Hani M. Babiker, Sumanta K. Pal, Michael Lilly, Benjamin L. Maughan, Benjamin Haaland, Mark Yandell, Oliver Sartor, Neeraj Agarwal
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BRCA1-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to BRCA2-mutated prostate cancer. The reason for this differential response is not clear. We hypothesized this differenti
Externí odkaz:
https://doaj.org/article/4e03b0f2c01f46158e4c977641bd2a04
Publikováno v:
European Urology Open Science, Vol 36, Iss , Pp 44-46 (2022)
Externí odkaz:
https://doaj.org/article/1d1f5b6a7acd4f5c9eea04205071395c